U.S. Paper and Forestry Products Stock News

In the past quarter, Hancock Whitney reported first-quarter 2026 adjusted earnings per share of US$1.52, ahead of expectations, as higher net interest income and modest loan growth helped offset a restructuring loss in its securities portfolio and a drop in non-interest income. Alongside these results, management outlined a 2026 outlook calling for modest growth in loans, deposits, and net interest income, while also filing a Form 144 for proposed insider share sales tied to 2020 stock...

The latest review by the independent Data Safety Monitoring Committee of EyePoint (EYPT) pivotal Phase 3 DURAVYU program kept both LUGANO and LUCIA trials on course, with interim masked data indicating a continued favorable safety profile. See our latest analysis for EyePoint. EyePoint’s recent safety update for DURAVYU comes after a sharp share price pullback this year, with the stock down 26.03% on a year to date share price return but still showing a 127.64% total shareholder return over...

It looks like Brookfield Infrastructure Corporation ( NYSE:BIPC ) is about to go ex-dividend in the next 4 days. The...

It's been a good week for Vipshop Holdings Limited ( NYSE:VIPS ) shareholders, because the company has just released...

Fastly recently reported strong growth in its Compute and Observability business, highlighting surging demand for AI-powered workloads at the edge and expanded customer co-innovation on complex use cases. A series of insider share sales in recent months, largely tied to tax obligations and pre-arranged trading plans, underscores that recent management transactions appear compensation-related rather than signaling operational change. Next, we’ll examine how Fastly’s accelerating AI-driven...

NervGen Pharma (NGEN) has drawn fresh attention after completing a follow on public equity offering of approximately $60 million, including common shares and warrants, to fund its neuroreparative drug development programs. See our latest analysis for NervGen Pharma. The follow on offering has coincided with sharp share price pressure, with NervGen Pharma’s 1 day share price return down 43.48% and its year to date share price return down 64.63%. This comes even though the 5 year total...

Earlier this week, Cardinal Health reported that quarterly revenue rose 11% year on year to US$60.94 billion, missing analysts’ revenue forecasts but beating full-year earnings-per-share guidance. Management highlighted the durability and resilience of the business, pointing to growth in its specialty portfolio, stronger free cash flow guidance for fiscal 2026, and ongoing share repurchases as key supports for its longer-term outlook. With Cardinal Health boosting free cash flow guidance and...

Gibraltar Industries (ROCK) is back on investors’ radar after a recent share price move, with the stock closing at US$37.18 as its recent performance and fundamentals draw closer attention. See our latest analysis for Gibraltar Industries. The recent 4.61% 1 day share price return and 5.09% 7 day share price return sit against a much weaker backdrop, with the 1 year total shareholder return down 37.07% and the 5 year total shareholder return down 53.20%. This suggests that recent momentum is...

In May 2026, Valley National Bancorp completed a US$500.00 million fixed‑to‑floating subordinated notes offering, announced the full redemption of its US$300.00 million 3.00% subordinated notes due 2031, and affirmed a quarterly common dividend of US$0.1100 per share payable on July 1, 2026. Together with board approvals, director equity grants, and a refreshed corporate social responsibility report, these capital and governance moves outline how Valley is reshaping its funding mix while...

Earlier this week, East West Bancorp filed two shelf registrations totaling US$483.76 million for ESOP-related common stock offerings and granted routine stock awards to non-employee directors following its 2026 Annual Meeting. Shareholders also endorsed all governance proposals, including refreshed stock incentive and employee stock purchase plans, signaling strong support for management’s long-term capital and compensation framework. With shareholders backing new stock plans and...

Earlier in May 2026, UroGen Pharma reported new Phase 3 data showing UGN-103 achieved a 94.5% six-month durability of response in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, closely mirroring outcomes seen with its approved intravesical therapy ZUSDURI. The company also highlighted long-term durability results for ZUSDURI and outlined plans to file an NDA for UGN-103 in the third quarter of 2026, aiming to expand its RTGel-based bladder cancer franchise and...

Why Nexa Resources Is On Investors’ Radar Today Nexa Resources (NEXA) stock has drawn fresh attention after a strong year to date return of 64.62%, prompting investors to reassess how its mining and smelting operations line up with current market expectations. See our latest analysis for Nexa Resources. At a share price of $14.47, Nexa Resources has seen firm momentum build over the past quarter, with a 90 day share price return of 23.57% and a 1 year total shareholder return of 194.28%...

Kymera Therapeutics (KYMR) is back in focus after showcasing expanded Phase 1b data for KT-621, its oral STAT6 degrader, at major dermatology and respiratory conferences. The company highlighted clinical signals in atopic dermatitis and asthma. See our latest analysis for Kymera Therapeutics. Despite the recent KT-621 data spotlight, Kymera Therapeutics’ share price has eased in the near term, with the 30 day share price return down 7.09% and the 90 day share price return down 10.79%. At the...

VinFast Auto (NasdaqGS:VFS) is back in focus after outlining plans to sell two factories in Vietnam to cut about US$6.9b of debt, alongside rolling out upgraded electric SUVs and expanding global after-sales support. See our latest analysis for VinFast Auto. The recent factory sale plan, upgraded VF 8 and VF 9 launches, and global service push arrive after a mixed run for investors. The share price is at US$3.57, with a 30 day share price return down 18.12%, a 90 day share price return up...

Earlier in May 2026, Mattel said it would lift spending by US$150,000,000 on mobile gaming, its Brick Shop initiative, and direct-to-consumer marketing, while simultaneously trimming its 2026 earnings-per-share guidance but committing to a US$1.50 billion share repurchase over three years. Alongside this heavier near-term investment, a cluster of routine director restricted stock unit settlements and a new Hot Wheels “Tiniest Team Principal” program highlight Mattel’s focus on both...

TransUnion (TRU) stock is back in focus after the company and Google introduced a new way for marketers to measure YouTube advertising within TransUnion’s Multi Touch Attribution solution, tying video ad exposure directly to business outcomes. See our latest analysis for TransUnion. At a share price of US$70.66, TransUnion’s 1-day and 7-day share price returns of 1.71% and 6.64% stand in contrast to a year-to-date share price decline of 15.20% and a 1-year total shareholder return decline of...

Earlier in May 2026, Skyward Specialty Insurance Group appointed industry veteran Melissa Goto as President of E&S Brokerage and Inland Marine and shareholders elected Peter C. Hearn to the board, adding deep underwriting and leadership expertise across complex specialty P&C markets. These leadership additions arrive as external analysts grow more optimistic about Skyward’s earnings outlook and its positioning in specialized commercial insurance niches. Next, we’ll explore how these analyst...

Sidus Space (SIDU) is back on radar after its mid May Q1 2026 report, which showed higher year over year revenue, a smaller net loss, and confirmation of a recent US$58.5 million capital raise. See our latest analysis for Sidus Space. The earnings update and April capital raise appear to have reset expectations, with the share price returning 152.22% over 90 days and total shareholder return of 228.21% over one year, despite a weaker three year total shareholder return. If Sidus Space’s...

Anterix (ATEX) has drawn attention after recent trading, with the stock last closing at $63.57 and showing strong short term and past 3 months moves. This has prompted investors to reassess its current pricing. See our latest analysis for Anterix. Recent momentum has been strong, with a 30 day share price return of 40.73% and a year to date share price return of 185.96%. The 1 year total shareholder return of 134.58% points to sustained interest over a longer period. If this kind of move has...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Expedia...

It looks like Copa Holdings, S.A. ( NYSE:CPA ) is about to go ex-dividend in the next 4 days. Typically, the...

Restaurant Brands International recently reported earnings that exceeded expectations, supported by steadier US Burger King same-store sales, and later held a fireside chat with its executive chairman and CEO at Bernstein’s 42nd Annual Strategic Decisions Conference, with the discussion streamed via its investor relations website. The combination of earnings outperformance and attention from high-profile investor Seth Klarman, who holds the company as his largest position, has sharpened...

Earlier in May 2026, BeOne Medicines received U.S. FDA accelerated approval for BEQALZI (sonrotoclax), a next-generation BCL2 inhibitor for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies including a BTK inhibitor. This first U.S. approval for sonrotoclax reshapes BeOne’s oncology profile by adding a new commercial pillar alongside its BTK franchise and broad late-stage pipeline. We’ll now examine how adding BEQALZI as an approved BCL2...